AbelZeta announces updated clinical results for C-CAR031 (AZD7003), a GPC3-targeted armored autologous CAR-T in advanced hepatocellular carcinoma at ESMO Congress 2026
Updated Phase I results of C-CAR031 in 36 heavily pretreated HCC patients demonstrated a disease control rate of 91.7% across all dose levels, with deep tumor shrinkages translating into an encouraging survival signal and a manageable safety profile, supporting further clinical...